Valneva Q1 Revenue Drops, Loss Widens; Focus on Cash as Lyme Vaccine Review Nears
VALN•Valneva’s first-quarter 2026 revenue fell year over year and its net loss widened as it conserves cash ahead of regulatory review of its Lyme disease vaccine candidate with Pfizer. The company said cost control remains a priority while awaiting a U.S. advisory committee meeting later this year.
1. First-Quarter 2026 Results
Valneva reported a year-over-year decline in Q1 2026 revenue and a wider net loss, citing reduced sales and increased R&D expenses. The company did not provide a detailed product breakdown but highlighted an overall contraction in its commercial portfolio.
2. Cash Conservation Measures
Management said it has prioritized extending its cash runway through stringent cost controls and postponing non-essential expenditures. The firm emphasized that maintaining liquidity will support operations until key regulatory milestones are achieved.
3. Lyme Disease Vaccine Regulatory Outlook
Valneva awaits a U.S. advisory committee meeting later this year to discuss its Lyme disease vaccine candidate developed with Pfizer. Approval and subsequent commercialization of this vaccine could significantly alter the company’s financial trajectory.
